Received: 14 November 2021 | Revised: 6 April 2022 | Accepted: 4 May 2022

DOI: 10.1002/med.21891

MINI REVIEW

Natural products as Zika antivirals

Yuhui Deborah Fong1,2 | Justin Jang Hann Chu1,2,3,4

1Integrative Sciences and Engineering Programme (ISEP), NUS Graduate School (NUSGS), National University of Singapore, Singapore, Singapore
2Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
3Infectious Diseases Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
4Collaborative and Translation Unit for HFMD, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore

Correspondence
Justin Jang Hann Chu, Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, 117545. Email: miccjh@nus.edu.sg

Funding information
Ministry of Education (MOE) Singapore, Grant/Award Numbers: MOE2017-T2-1-078, MOE2017-T2-2-014; National Research Foundation, Grant/Award Number: NRF-CRP21-2018-0004

Abstract
Zika virus (ZIKV) is an arbovirus belonging to the flavivirus genus and is transmitted in Aedes mosquito vectors. Since its discovery in humans in 1952 in Uganda, ZIKV has been responsible for many outbreaks in South America, Africa, and Asia. Patients infected with ZIKV are usually asymptomatic; mild symptoms include fever, joint and muscle pain, and fatigue. However, severe infections may have neurological implications, such as Guillain-Barré syndrome and fetal microcephaly. To date, there are no existing approved therapeutic drugs or vaccines against ZIKV infections; treatments mainly target the symptoms of infection. Preventive measures against mosquito breeding are the main strategy for limiting the spread of the virus. Antiviral drug research for the treatment of ZIKV infection has been rapidly developing, with many drug candidates emerging from drug repurposing studies, and compound screening. In particular, several studies have demonstrated the potential of natural products as antivirals for ZIKV infection. Hence, this paper will review recent advances in natural products in ZIKV antiviral drug discovery.

KEYWORDS
antiviral, drug discovery, infectious disease, natural product, Zika virus

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2022 The Authors. Medicinal Research Reviews published by Wiley Periodicals LLC.
1 | INTRODUCTION

Zika virus (ZIKV) is an arbovirus belonging to the genus Flavivirus and is mainly transmitted in Aedes mosquito vectors, namely Aedes aegypti and Aedes albopictus. Since its discovery in humans in 1952 in Uganda, ZIKV has been responsible for many outbreaks in South America, Africa, and Asia, with the first recorded outbreak being in the Federated States of Micronesia in 2007. The World Health Organisation (WHO) reported that as of July 2019, 87 countries have been identified to have indigenous mosquito-borne transmission of ZIKV. One of the largest outbreaks occurred in French Polynesia in 2013, where over half the population was estimated to be infected with ZIKV. A retrospective study of this outbreak revealed that 66% of the population was infected with ZIKV, and eight microcephaly cases were diagnosed in neonates. In light of the rapid transmission of ZIKV and its association with neurological disorders, WHO declared ZIKV infection to be a Public Health Emergency of International Concern on 1 February 2016.

Although there has been a decrease in the number of reported cases each year in the recent few years, this does not indicate the elimination of ZIKV transmission. In addition to logistical issues in routine surveillance and testing of suspected cases, patients infected with ZIKV are usually asymptomatic; mild symptoms include fever, joint and muscle pain, and fatigue. Such symptoms are often misdiagnosed as other viral infections as they are nonspecific, hence the difficulty in reporting and tracking ZIKV transmission. Furthermore, evidence for ZIKV transmission by sexual intercourse has also been uncovered, indicating that it is not just tropical countries that are at risk of ZIKV outbreaks.

Severe ZIKV infections are associated with neurological disorders, such as Guillain-Barré syndrome in adults. ZIKV patients who are pregnant also are at increased risk of giving birth to children with congenital Zika syndrome, a group of birth defects, including fetal microcephaly brain calcification, and abnormal brain development. These complications are not observed in other flaviviral infections, which makes early diagnosis and treatment of ZIKV infections of paramount importance.

To date, there are no existing approved therapeutic drugs or vaccines against ZIKV infections; treatments primarily target the symptoms of infection. These include sufficient rest and taking acetaminophen. Preventive measures against mosquito breeding are the main strategy for limiting the spread of the virus. Antiviral drug research for the treatment of ZIKV infection has been rapidly developing, with many drug candidates emerging from drug repurposing studies, and compound screening. In particular, several studies have demonstrated the potential of natural products as antivirals for ZIKV infection. Natural products are a key source of compounds for drug discovery, as they tend to have favourable physicochemical properties and lower toxicity. Natural products such as flavonoids are abundant in food and plants, and have been demonstrated to have antitumour and anti-inflammatory properties. They can also be derived from living organisms which produce secondary metabolites that are nonessential for key processes but enhance survival of the organisms. Hence, the diversity of compounds in natural products is a library of interest to explore for their antiviral properties against ZIKV. This paper will thus review recent advances in natural products in ZIKV antiviral drug discovery. The origins of the natural products, their chemical classes, and future perspectives will be discussed.

2 | GENERAL VIROLOGY

The ZIKV genome consists of a single-stranded positive-sense RNA of about 10.7 kb in length. The 5’-untranslated region (UTR) and 3’-UTR is about 100 and 420 nucleotides, respectively. Translation of the open reading frame results in a large polyprotein consisting 3423 amino acids. This large polyprotein is processed by host and viral proteases to give rise to three structural and seven nonstructural proteins (Figure 1). The structural proteins C, prM and E, have key roles in viral entry and release of new virions from the host cell. The
C protein is responsible for forming the nucleocapsid core surrounding the viral genome; the E protein facilitates virion binding to the receptor on the host cell membrane. The prM protein, once processed, aids in ensuring the spatial structure of the E protein. Similar to other flaviviruses, the nonstructural proteins are part of the viral replication complex in the host cell cytoplasm. Notably, the NS5 protein functions as the viral RNA-dependent RNA polymerase (RdRp), which reads the positive-sense RNA genome to give the negative-sense RNA strand which is then used for translation in producing the large polyprotein precursor. In addition, the NS3 protein contains serine protease and RNA helicase domains, which works to cleave the large polyprotein to give active proteins. The other nonstructural proteins are also involved in viral assembly and replication in the host cell, ensuring that the replication complex is anchored in the ER membrane for effective viral replication.

The ZIKV replication cycle is illustrated in Figure 2. When an Aedes mosquito vector carrying ZIKV feeds on a mammalian host, ZIKV virions are released into the bloodstream of the host; binding to receptors on the host cell surface is facilitated by the E protein. One example is the cellular receptor Axl which binds to phosphatidylserine on the surface of the ZIKV. Through receptor-mediated endocytosis, clathrin-coated vesicles encapsulate the virus and bud off from the host cell membrane. The low pH environment in the endosome results in the fusion of the viral capsid and the endosome, releasing the nucleocapsid into the cell cytoplasm. The positive-sense RNA is then translated on the membrane of the rough endoplasmic reticulum and an immature virion is assembled, with the help of the nonstructural proteins. This immature virion moves into the Golgi apparatus, where further post-translational modifications such as carbohydrate addition and proteolytic cleavage occur on the prM protein. The virion then moves towards the host cell membrane, where it acquires the membrane envelope and is released via exocytosis as a mature virion.

The following sections will discuss compounds according to the stage of the ZIKV replication cycle targeted (Table 1). Where possible, similar regions in molecular structures (potential pharmacophores) within each group of compounds will be highlighted. The compounds described here are potential starting points for further hit-to-lead or structure-activity relationship (SAR) studies to improve on the efficacy and physicochemical properties of these potential lead compounds.

3 | VIRAL ENTRY INHIBITORS

Viral entry is a common stage of the viral replication cycle to target, as these inhibitors can be used as prophylactic treatments. In addition, as membrane permeability into the host cell is not a requirement, compounds inhibiting viral entry tend to be less toxic. The process of viral entry itself is multifaceted, with different viral-host interactions involving host cell surface receptors and the ZIKV E protein. Hence, it is unsurprising that a large number of ZIKV natural product antivirals target this stage of the viral replication cycle.
Inhibitors with direct virucidal effects

Viral entry inhibitors can be divided into two subclasses, namely those that exhibit direct virucidal effects on the viral envelope itself and those that target host cell receptors or viral-host interactions.

Labyrinthopeptins are a type of lantibiotic, which is a peptide antibiotic consisting of unusual amino acids. Labyrinthopeptins A1 and A2 (LabyA1 and LabyA2) are peptides produced in the bacteria actinomycete Actinomadura namibiensis DSM 6313. Using high-content imaging and immunofluorescence, Prochnow et al. showed the broad-spectrum antiviral activity of LabyA1 and LabyA2 against not just flaviviruses but other viruses.
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC₅₀/EC₅₀ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|---------------------------------------|-----------------------------|-----------|---------------------|-----------------------------------------------|
| 1   | Labyrinthopeptin A1                   | Binds to viral membrane lipid phosphatidylethanolamine and disrupts viral membrane envelope | A1: 2.0 μM, 1.6 μM  
A2: 9.6 μM, 3.3 μM | 976, H/PF/2013 | In vitro: Huh-7¹  
In vivo: injected i.v and i.p into 4-week-old male CD-1 mice at 10 mg/kg¹ |

![Diagram of Labyrinthopeptin A1](image1)

![Diagram of Labyrinthopeptin A2](image2)

*Differences in amino acid residues are highlighted in blue. Lab: labionin; Dhb: didehydrobutyrine.

Source: *Actinomadura namibiensis* DSM 6313

(Continues)
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC₅₀/EC₅₀ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|----------------------------|----------|----------------------|-----------------------------------------------|
| 2   | Delphinidin                            | Virucidal effect on virus particles | -        | PA259459, MR766      | In vitro: Vero ³                              |

Source: Various fruits ²

| 3   | Epigallocatechin gallate (EGCG)        | Inhibits NS2B-NS3 viral protease, NS3 helicase, and has virucidal effect on virus particles | 21.4 µM; 0.02 ± 0.003 µM | PA259459, MR766, Brazilian strain, Z16006 | In silico molecular docking ⁸ |

Source: Green tea
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC$_{50}$/EC$_{50}$ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|---------------------|----------------------|--------------------------------------------------|
| 4   | Baicalein                              | Inhibits a post-entry step and has virucidal effect on virus particles | 0.004 µM           | PRVABC59            | In vitro: Vero$^9$ In silico molecular docking$^9$ |
|     | ![Baicalein Chemical Structure](image) |                             |                     |                      |                                                 |
|     | Source: *Scutellaria baicalensis & Scutellaria lateriflora* |                             |                     |                      |                                                 |
| 5   | Baicalin                               | Inhibits viral entry and has virucidal effect on virus particles | 14 µM              | PRVABC59            | In vitro: Vero$^9$ In silico molecular docking$^9$ |
|     | ![Baicalin Chemical Structure](image) |                             |                     |                      |                                                 |
|     | Source: *Scutellaria baicalensis & Scutellaria lateriflora* |                             |                     |                      |                                                 |
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC_{50}/EC_{50} | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|---------------------------------------|-----------------------------|------------------|----------------------|-----------------------------------------------|
| 6   | Gossypol | Virucidal effect on virus particles | 0.21–4.31 µM | PAN2016, R116265, PAN2015, FLR, R103451, | In vitro: Vero, purified E protein^{11} |

Source: Plants of the *Gossypium* genus^{10}

| Source: *Gossypium* genus^{10} |

| 7   | Ginkgolic acid | Inhibits early stages of viral replication, possibly due to its virucidal activity | - | 259249 | In vitro: Vero^{12} |

Source: *Ginkgo biloba*
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC\(_{50}\)/EC\(_{50}\) | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|-----------------|----------------------|-----------------------------------------------|
| 8   | Emodin                                 | Inhibits viral entry and has virucidal effect on virus particles | 3.2 µM          | Brazilian strain     | In vitro: Vero\(^{14}\), Vero E\(_{6}\)\(^{15}\) |
|     | ![Emodin Chemical Structure](image)    |                             |                 |                      |                                               |
|     | Source: Various plant species\(^{13}\) |                             |                 |                      |                                               |
| 9   | Resveratrol                            | Inhibits a post-entry step and has virucidal effect on virus particles | 93% (1 log) reduction in foci | P6740, MR766, PE243 | In vitro: Vero\(^{14}\), Huh-7\(^{17}\), HTR-8/SVneo\(^{18}\), Vero E\(_{6}\)\(^{18}\) |
|     | ![Resveratrol Chemical Structure](image) |                             |                 |                      |                                               |
|     | Source: Various plant species\(^{16}\) |                             |                 |                      |                                               |
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC₅₀/EC₅₀ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|-----------|----------------------|-----------------------------------------------|
| 10  | Berberine | Virucidal effect on virus particles | 39.06 µM | Brazilian strain | In vitro: Vero E₆₁⁵ |
|     | ![Berberine chemical structure](source: Berberis vulgaris) | | | | |
| 11  | Cephalotaxine | Inhibits post-entry step of viral replication, possibly interfering with viral RNA translation. Virucidal effect also observed. | - | PRVABC59 | In vitro: Vero₂₀ A₁⁸⁴⁹ |
|     | ![Cephalotaxine chemical structure](source: Cephalotaxus drupacea) | | | | |
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC₅₀/EC₅₀ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|----------|-----------------------|-----------------------------------------------|
|     |                                        | Blocks clathrin-mediated endocytosis, inhibiting viral entry | 0.1 µM | MR766, MEX 2-81, FSS13025 | In vitro: U2OS, human brain microvascular endothelial cells, Vero, JEG-3 |
| 12  | Nanchangmycin                          |                             |          |                       |                                               |
|     | Source: *Streptomyces nanchangensis*    |                             |          |                       |                                               |

Inhibitors targeting the viral entry process

| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC₅₀/EC₅₀ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|----------|-----------------------|-----------------------------------------------|
| 13  | Quercetin                              | Inhibits NS2B-NS3 viral protease and viral entry, possibly by targeting the virus particle itself or host cell surface proteins | NS2B-NS3pro: 1.17 ± 0.22 µM; 2.4 ± 0.2 µM | MR766, Z16006 | In vitro: Vero, purified ZIKV NS2B-NS3pro, In silico molecular docking |
|     |                                        |                             |          |                       |                                               |

Source: Various plant species

(Continues)
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC$_{50}$/EC$_{50}$ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|--------------------------------------|----------------------------|---------------------|----------------------|-----------------------------------------------|
| 14  | Kaempferide                           | Inhibits viral entry and NS2B-NS3 viral protease | NS2B-NS3$^{a}$ pro: 7.18 ± 2.16 µM | Z16006 | In vitro: Vero,$^{a}$ purified ZIKV NS2B-NS3$^{a}$ pro |
| 15  | Galangin                              | Inhibits viral entry and NS2B-NS3 viral protease | NS2B-NS3$^{a}$ pro: 25.68 ± 9.17 µM | Z16006 | In vitro: Vero,$^{a}$ purified ZIKV NS2B-NS3$^{a}$ pro |

Source: Kaempferia galanga

Source: Alpinia officinarum Hance$^{25}$
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC$_{50}$/EC$_{50}$ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|---------------------|----------------------|-----------------------------------------------|
| 16  | Isoquercetin                            | Inhibits viral entry        | 1.2–1.3 µmol/L; 9.7–15.5 µM | PF-25013-18, MR766   | In vitro: A549,26 Huh-7,26 SH-SYSY,26 Vero27  |
|     |                                        |                             |                     |                      | In vivo: injected via i.p. into 6–8-week-old male or female Ifnar1$^-/-$ mice at 50 mg/kg27 |

Source: Various plant species22
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC₅₀/EC₅₀ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|--------------------------------------|-----------------------------|-----------|----------------------|-----------------------------------------------|
| 17  | Ellagic acid                          | Reduces cell susceptibility to the virus by binding to host cell surface | 30.86 µM | MR766, H/PF/2013      | In vitro: Vero |  |
|     | Source: *Punica granatum*             |                             |           |                      |                                               |  |
| 18  | Curcumin                              | Inhibits viral entry or binding and NS2B-NS3 viral protease | NS2B-NS3<sup>prog</sup>: 3.5 ± 0.2 µM | PAN2016, R116265, PAN2015, FLR, R103451, PRVABC59, PLCal_ZV, IbH 30656, MEX 2–81, MR766, HD78788 | In vitro: Vero E<sub>6</sub>,<sup>11</sup> HeLa,<sup>29</sup> purified ZIKV E protein,<sup>11</sup> NS2B-NS3<sup>pro</sup><sup>24</sup> |  |
|     | Source: *Curcuma longa* (Turmeric)    |                             |           |                      |                                               |  |
| S/N | Compound name/Chemical structure/Source               | Proposed mode of inhibition                  | IC_{50}/EC_{50}       | ZIKV strain(s) tested               | In vitro cell lines/in vivo animal models studied |
|-----|------------------------------------------------------|----------------------------------------------|----------------------|------------------------------------|-------------------------------------------------|
| 19  | Digitonin [Source: Digitalis purpurea]              | Inhibits viral entry                        | 3.19−6.52 µM         | PAN2016, R116265, PAN2015, FLR, R103451, PRVABC59, PLCal_ZV, IbH 30656, MEX 2−81, MR766 | In vitro: Vero E6\(^{11}\)                      |
| 20  | Conessine [Source: Digitalis purpurea]              | Inhibits virus-cell attachment or a postentry step | 7.18−11.60 µM       | PAN2016, R116265, PAN2015, FLR, R103451, | In vitro: Vero E6\(^{11}\)                      |
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC$_{50}$/EC$_{50}$ | ZIKV strain(s) tested                           | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|----------------------------|---------------------|-----------------------------------------------|-----------------------------------------------|
| 21  | Viral replication inhibitors            | Inhibits host endoplasmic reticulum signal peptidase, preventing viral replication | 150 nM              | FSS13025                                      | In vitro: A549 [31]                           |

**Source:** *Holarrhena antidysenterica* $^{30}$

**Source:** *Colispora cavincola*
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC₅₀/EC₅₀ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|----------|----------------------|------------------------------------------------|
| 22  | Sinefungin ![Image](image1.png) Source: *Streptomyces griseoleus* | Competitively binds to viral NS5 methyltransferase instead of S-adenosylmethionine (SAM), prevents the methylation of the cap structure of viral RNA | 1.18 ± 0.05 µM | H/PF/2013, MR766 | In vitro: purified ZIKV NS5 methyltransferase³²,³³ |
| 23  | FV13 ![Image](image2.png) Source: Chrysin-derivative³⁴ | Multiple targets, likely to target a postgenome replication step | 1.65 ± 0.86 µM | SV0010/15 | In vitro: LLC/MK2³⁵ |

(Continues)
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC₅₀/EC₅₀ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|----------------------------|------------|----------------------|-----------------------------------------------|
| 24  | FV14                                   | -                          | 1.39 ± 0.11 µM | SV0010/15            | In vitro: LLC/MK2³⁵                         |
|     | ![FV14 structure](image1.png)           | Source: Chrysin-derivative³⁴|            |                      |                                               |
| 25  | Pinocembrin                             | Inhibits viral RNA and envelope protein synthesis | 17.4 µM | PRVABC59            | In vitro: JEG-3, Huh-7³⁶                     |
|     | ![Pinocembrin structure](image2.png)    | Source: Various plant species³⁷ |            |                      |                                               |
**TABLE 1**  (Continued)

| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC_{50}/EC_{50} | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|--------------------------------------|-----------------------------|----------------|----------------------|-----------------------------------------------|
| 26  | Sophoraflavenone G (SFG)              | Inhibits NS5 RdRp activity   | 22.61 µM       | FSS13025             | In vitro: primary human trophoblasts, 38 AS49 38 |
|     | Source: Sophora flavescens            |                             |                |                      |                                               |
| 27  | Cephaeline                            | Inhibits NS5 RdRp activity and disrupts host cell lysosomal function | NS5 RdRp: 976 nM, MR766, PRVABC59, FSS13025, Brazilian strain | 7.60 nM | In vitro: HEK293, 39 SNB-19, Vero E6, purified ZIKV NS5 RdRp |
|     | Source: Carapichea ipecacuanha        |                             |                |                      |                                               |

(Continues)
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC$_{50}$/EC$_{50}$ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|---------------------|----------------------|------------------------------------------------|
| 28  | Emetine | Inhibits NS5 RdRp activity and disrupts host cell lysosomal function | NS5 RdRp: 121 nM | MR766, PRVABC59, FSS13025, Brazilian strain | In vitro: HEK293, 39 SNB-19, Vero E6, purified ZIKV NS5 RdRp |

Source: *Carapichea ipecacuanha*
### Table 1 (Continued)

| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC_{50}/EC_{50} | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|-----------------|----------------------|--------------------------------------------------|
| 29  | Lycorine                               | Inhibits NS5 RdRp activity   | 0.22–0.39 µM    | KU963796             | In vitro: Vero, A549, Huh-7, purified ZIKV NS5 RdRp In vivo: intragastric administration in 4–5-week-old AG6 mice at 1–10 mg/kg^{40} |
|     | Source: Various Amaryllidaceae species^{41} |                             |                 |                      | In silico molecular docking^{40}                   |
| 30  | Silvestrol                             | Inhibits host cell factor eIF4A | -               | 976, H/PF/2013       | In vitro: A549, primary human hepatocytes         |

Source: Aglaia foveolata

(Continues)
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC₅₀/EC₅₀ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|---------------------------------------|-----------------------------|----------|----------------------|------------------------------------------------|
| 31  | Novobiocin                             | Competitively binds to NS2B-NS3 viral protease | 42.63 µM | PRVABC59             | In vitro: Vero,⁴³ Huh-7, purified ZIKV NS2B-NS3pro In vivo: injected subcutaneously into dexamethasone-immunosuppressed BALB/c mice at 100 mg/kg⁴³ |
|     | Source: *Streptomyces niveus*          |                             |          |                      |                                                |
| 32  | Apigenin                               | Noncompetitive inhibitor of NS2B-NS3 viral protease | 56.3 ± 0.9 µM | -                   | In vitro: purified ZIKV NS2B-NS3pro⁴⁴ In silico molecular docking⁴⁴ |
|     | Source: *Apiaceae* family plants⁴⁴    |                             |          |                      |                                                |
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC_{50}/EC_{50} | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|-----------------|-----------------------|-----------------------------------------------|
| 33  | Astragalin                              | Inhibits NS2B-NS3 viral protease | 112 ± 5.5 µM    | -                     | In vitro: purified ZIKV NS2B-NS3^{pro7}        |
| 34  | Epicatechin gallate (ECG)               | Inhibits NS2B-NS3 viral protease | 89 ± 1.6 µM     | -                     | In vitro: purified ZIKV NS2B-NS3^{pro7}        |

Source: Various plant species^{45}

Source: Green tea
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC$_{50}$/EC$_{50}$ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|-------------------|---------------------|------------------------------------------------|
| 35  | Gallicatechin gallate (GCG)            | Inhibits NS2B-NS3 viral protease | 99 ± 1.8 µM       | -                   | In vitro: purified ZIKV NS2B-NS3pro$^{46}$       |
|     | ![Chemical structure](image1.jpg)     |                             |                   |                     |                                                |
|     | Source: Green tea                     |                             |                   |                     |                                                |
| 36  | Isorhamnetin                          | Inhibits NS2B-NS3 viral protease | 15.5 ± 0.7 µM     | -                   | In vitro: purified ZIKV NS2B-NS3pro$^{46}$       |
|     | ![Chemical structure](image2.jpg)     |                             |                   |                     |                                                |
|     | Source: Various plant species$^{46}$  |                             |                   |                     | In silico molecular docking$^{46}$               |
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC_{50}/EC_{50} | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|--------------------------------------|----------------------------|-----------------|----------------------|-----------------------------------------------|
| 37  | Luteolin                             | Noncompetitive (allosteric) inhibitor of NS2B-NS3 viral protease | 2.7 ± 0.3 µM; 53 ± 1.3 µM | -                    | In vitro: purified ZIKV NS2B-NS3<sup>4,7,24</sup> |
|     |                                      |                            |                 |                      | In silico molecular docking<sup>24</sup>       |
|     | ![Luteolin Chemical Structure](image) |                            |                 |                      |                                               |
| 38  | Myricetin                            | Inhibits NS2B-NS3 viral protease via mixed inhibition | 1.10–22 µM      | Z16006               | In vitro: Vero<sup>4</sup>, purified ZIKV NS2B-NS3<sup>4,7,24</sup> |
|     |                                      |                            |                 |                      | In silico molecular docking<sup>4,24</sup>     |
|     | ![Myricetin Chemical Structure](image) |                            |                 |                      |                                               |

Source: Various plant species<sup>47</sup>,<sup>22</sup>
| S/N | Compound name/Chemical structure/Source | Proposed Mode of inhibition | IC<sub>50</sub>/EC<sub>50</sub> | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|-------------------|----------------------|-----------------------------------------------|
| 39  | Rutin                                  | Inhibits NS2B-NS3 viral protease | 104 ± 2.9 µM | -                    | In vitro: purified ZIKV NS2B-NS3<sup>a</sup> |
| 40  | Naringenin                             | Inhibits a postentry step, possible noncompetitive inhibitor of NS2B-NS3 viral protease | 58.79 µM | BR 2015/15261, BR 2015/15098, BR 2016/16288, PE243 | In vitro: A549<sup>b</sup>,<sup>c</sup>,<sup>d</sup>,<sup>e</sup> |

<sup>a</sup> Source: Various plant species

<sup>b</sup> In silico molecular docking

<sup>c</sup> Source: Various citrus fruits
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC$_{50}$/EC$_{50}$ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|---------------------|----------------------|-----------------------------------------------|
| 41  | Marinopyrrole derivative (Compound 1)  | -                           | 5.95 ± 0.72 µM      | NR-50210             | In vitro: Vero$^{52}$                        |
| 42  | Kitasamycin                            | -                           | 41.7 ± 10.1 µM      | PE243                | In vitro: Huh-7$^{53}$                       |

Source: Actinomycete strain CNQ-418 derivative

Source: Streptomyces narbonensis
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC₅₀/EC₅₀ | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|----------|----------------------|------------------------------------------------|
| 43  | Hippeastrine hydrobromide (HH)         | -                           | 1.95 μM  | MR766               |                                               |

Source: Lycoris radiata

In vitro: human pluripotent stem cell (hPSC)-derived human cortical neural progenitor cells (hNPCs), human fetal-like forebrain organoid model

In vivo: injected subcutaneously in 6–8-week-old in severe combined immunodeficiency beige (SCID-beige) mice at 100 mg/kg/day
| S/N | Compound name/Chemical structure/Source | Proposed mode of inhibition | IC_{50}/EC_{50} | ZIKV strain(s) tested | In vitro cell lines/in vivo animal models studied |
|-----|----------------------------------------|-----------------------------|-----------------|----------------------|-----------------------------------------------|
| 44  | 18-oxoferuginol                       | -                           | 2.60 ± 0.07 µM  | IMT17                | In vitro: Vero<sup>25</sup>                   |

Source: *Sequoia sempervirens*
such as herpes simplex virus without high toxicity. LabyA1 inhibited ZIKV-976 with an IC$_{50}$ value of 2.0 µM; LabyA2 inhibited ZIKV-976 with an IC$_{50}$ value of 9.6 µM. Mechanistic studies revealed that LabyA1 and LabyA2 bind directly to virus particles to exhibit their antiviral effect. In particular, the labyrinthopeptins bind to phosphatidylethanolamines present as membrane lipids on the surface of the virus particles. This disrupts the viral envelope, leading to virolysis. Both LabyA1 and LabyA2 were also shown to work synergistically and display good preliminary pharmacokinetic properties when administered in male CD1 mice.

Cirne-Santos et al.\textsuperscript{39} investigated the anti-ZIKV activity of crude extracts from the Brazilian brown seaweed Dictyota menstrualis. Brown seaweeds of this genus are rich in cyclic diterpenes and have been investigated for their antiviral effects on human immunodeficiency virus.\textsuperscript{40,41} It was found that fraction FAc-2 exhibited virucidal effects on ZIKV particles, inhibiting >90% of viral activity at a 20 µg/ml concentration.

In addition to compounds and fractions of microbial and marine origin, plants are a rich source of antivirals. Epigallocatechin gallate (EGCG) is a flavanol found in a large quantity in green tea and has known antiviral effects against many other viruses.\textsuperscript{42} Carneiro\textsuperscript{22} and colleagues showed the direct virucidal effect of EGCG on ZIKV particles with an EC$_{50}$ value of 21.4 µM, inhibiting viral entry. Building upon the current findings, another study identified the site of EGCG binding on the E protein of ZIKV, and showed the key amino acid residues of the E protein involved in interacting with the compound via induced-fit docking and molecular dynamics simulations.\textsuperscript{43}

Through a similar method, the interaction of EGCG with NS3 helicase was investigated, which showed possible binding of EGCG to both the RNA site and NTPase site of NS3 helicase.\textsuperscript{44} In vitro NTPase activity inhibition by EGCG was shown to be 295.7 nM, confirming the results obtained in silico. EGCG was also identified in another screen of six structurally related polyphenols conducted by Vázquez-Calvo et al.,\textsuperscript{45} where the virucidal effects of both delphinidin and EGCG on ZIKV was observed. A concentration of 10 µM was able to decrease viral plaque formation by approximately 10-fold. Further analysis via quantitative reverse transcription-polymerase chain reaction revealed both delphinidin and EGCG to result in a reduction of viral RNA in the infected culture supernatant.

Flavones baicalein and baicalin from Chinese herbs Scutellaria baicalensis and Scutellaria lateriflora were investigated for their anti-ZIKV effect in Vero-infected cells.\textsuperscript{46} Baicalein had the lowest EC$_{50}$ value of 0.004 µM when it was introduced post-entry; baicalin had the lowest EC$_{50}$ value of 14 µM when it was introduced at the point of entry. Both compounds also showed direct virucidal effect on ZIKV particles. In silico studies revealed the two compounds had the strongest binding affinity to viral NS5. In addition, both baicalein and baicalin have long half-lives of 15.01 and 9.65 h respectively, and have favourable pharmacokinetic properties, making them ideal candidates for lead optimisation.\textsuperscript{47}

Gossypol was identified in a natural product library screen of Vero-infected cells by Gao et al.,\textsuperscript{48} exhibiting the highest inhibitory activity among the hits identified against various ZIKV strains (IC$_{50}$ range: 0.21–4.31 µM). Time-of-addition experiments revealed its potent virucidal effect on virus particles; enzyme-linked immunoassay and surface plasmon resonance experiments confirmed the high binding affinity of gossypol for the ZIKV E protein (EC$_{50}$: 7.12 µM; K$_D$: 2.19 µM).

Ginkgolic acid is a phenolic acid extracted from the seed coats or leaves of Ginkgo biloba. Plaque-forming assays showed ginkgolic acid to be able to block ZIKV replication in Vero cells in a dose-dependent manner.\textsuperscript{51} Time-of-addition experiments showed that ginkgolic acid affects the early stages of viral replication, possibly due to its virucidal activity.

Emodin, an anthraquinone derivative that can be found in various Chinese herbs, was shown by to reduce ZIKV viral titre in Vero cells (IC$_{50}$: 3.2 µM).\textsuperscript{49} Emodin reduced viral entry by 42.31% and produced a virucidal effect on virus particles. It was postulated that the virucidal effect is due to the high affinity of emodin for the phospholipid bilayer of the viral envelope. This is evidenced by a change in the hydrodynamic radii of ZIKV virus particles before and after incubation with emodin when measured via dynamic light scattering, possibly indicating a disruption of the phospholipid bilayer of virus particles.
Resveratrol is produced by several plant species, and is usually extracted from red grapes and red wine.\textsuperscript{50} Resveratrol has been widely researched on for its antioxidant, anti-inflammatory, and anticancer properties.\textsuperscript{52} Results showed treatment of Huh7-infected cells with 80 µM resveratrol reduced the number of foci formed by 93% (1 log) and is likely to have direct virucidal activity and post-entry inhibition of the ZIKV replication cycle.

Berberine, an isoquinoline alkaloid isolated from Berberis vulgaris, was assessed by Batista and lab for its anti-ZIKV activity on Vero cells.\textsuperscript{49} Berberine reduced ZIKV viral titre with an IC\textsubscript{50} value of 39.06 µM and was identified to do so via a direct virucidal effect.

Cephalotaxine is an alkaloid isolated from the plant Cephalotaxus drupacea, shown by Lai, Ho, and Lu\textsuperscript{53} to inhibit ZIKV infection in A549 cells in a dose-dependent manner. Further analysis revealed that viral RNA was reduced in Vero cells when cephalotaxine was added post-infection and throughout infection, indicating that cephalotaxine exhibits inhibition after virus entry. It was hypothesised that cephalotaxine works by interfering with viral RNA translation. In addition, a virucidal effect on ZIKV particles was observed.

Many of the compounds mentioned above do not just exhibit virucidal effects, but are bifunctional in targeting two different stages of the ZIKV replication cycle, such as EGCG which targets both viral entry and NS3 helicase. This bifunctional aspect could be leveraged on in drug development as for the same dose, dual effects are achieved.

3.2 | Inhibitors targeting the viral entry process

These inhibitors prevent the successful internalisation of the virus by disrupting viral-host cell interactions or by blocking host cell factors that mediate the endocytosis of the viral capsid.\textsuperscript{54} The same study carried out by Cirne-Santos and colleagues on crude extracts from D. menstrualis.\textsuperscript{39} In addition to fraction FAc-2 exhibiting virucidal effects on ZIKV particles, fraction F-6 from the crude extract was found to reduce viral activity via inhibition of viral adsorption into host cells.

Nanchangmycin is an antibiotic produced by Streptomyces nanchangensis and shown to inhibit Gram-positive bacteria. Rausch\textsuperscript{56} and co-workers carried out a high-throughput image-based screen on a library of bioactive compounds against ZIKV and identified nanchangmycin to be a potent inhibitor with an IC\textsubscript{50} of 0.1 µM in U2OS cells. Nanchangmycin also exhibited inhibitory effects on other viruses with the same internalisation pathway as ZIKV such as chikungunya and sindbis viruses. However, nanchangmycin had no effect on parainfluenza 5 virus which does not share the same internalisation pathway as ZIKV. This suggests that nanchangmycin likely acts by blocking clathrin-mediated endocytosis.

Zou\textsuperscript{55} and colleagues further added on to the research by investigating the inhibitory effects of several flavonoids on ZIKV-infected Vero cells in vitro.\textsuperscript{56} Plaque reduction assays revealed the flavonols quercetin (IC\textsubscript{50}: 2.30 ± 0.50 µM), myricetin (IC\textsubscript{50}: 0.58 ± 0.17 µM), galangin (IC\textsubscript{50}: 14.36 ± 9.5 µM), and kaempferide (IC\textsubscript{50}: 5.83 ± 1.92 µM) to be potent inhibitors of ZIKV infection, with high CC\textsubscript{50} values indicating low cytotoxicity. The flavanol EGCG was the most potent among the five compounds, with an IC\textsubscript{50} of 0.02 ± 0.003 µM and CC\textsubscript{50} of more than 500 µM. Time-of-addition assays showed that these flavonoids mediate the highest inhibition when co-incubated with the virus, inhibiting viral entry. In addition, a biochemical enzymatic assay with ZIKV NS2B-NS3 protease was performed, confirming that these five compounds are also able to inhibit ZIKV NS2B-NS3 protease activity, with EC\textsubscript{50} values ranging from 0.73 to 25.68 µM. Based on the data obtained, Zou\textsuperscript{55} and colleagues postulated that the IC\textsubscript{50} values decreased when the number of hydroxyl groups increased on the molecule. Furthermore, the galloyl group on EGCG seems to be responsible for the formation of crucial hydrogen bonds that give rise to the low IC\textsubscript{50} value of EGCG. This study has thus showed the dual function of flavonoid inhibitors in inhibiting both ZIKV viral entry and ZIKV NS2B-NS3 protease activity.

Isoquercetin, a glycoside derivative of quercetin which is a flavonol found in various plant species, was also found to have anti-ZIKV activity in several studies, being able to reduce viral replication in Vero-infected cells.
Preliminary studies in immunocompromised mice (Ifnar1−/−) vulnerable to ZIKV infection showed the protective efficacy of isoquercetin in increasing survival and reducing weight loss. Another study reported the IC50 of isoquercetin in multiple cell lines (A549, Huh-7, SH-SY5Y) to be between 9.7 and 15.5 µM, and showed that isoquercetin targets the initial stages of ZIKV infection, particularly that of virus internalisation. Another study on ellagic acid, a polyphenol identified and isolated from the *P. granatum* plant (commonly known as pomegranate), demonstrated its possible mechanism of action by binding to host cell surface and reducing cell susceptibility to the virus. Curcumin is a component of turmeric, and has been shown to have antibacterial, antifungal and antiviral effects. Mounce and co-workers showed the anti-ZIKV effect of curcumin on HeLa cells to be through inhibition of virus binding to the cell surface (IC50: 1.90 µM), as transfection of ZIKV bypassed curcumin inhibition. Derivatives of curcumin such as bisdemethoxycurcumin and demethoxycurcumin showed similar inhibitory activity as unmodified curcumin. Digitonin is a steroidal saponin in the class of terpenoids, which are characterised by the five-carbon isoprene structure. Digitonin was a positive hit in a natural product library screen by Gao and colleagues, with IC50 values against various ZIKV strains ranging from 3.19 to 6.52 µM. Time-of-addition experiments showed digitonin to inhibit viral entry. Conessine, a steroidal alkaloid, was another hit identified in the natural product library screen by Gao and colleagues, with IC50 values ranging from 7.18 to 11.60 µM against a variety of ZIKV strains. From time-of-addition experiments, it is likely that conessine targets the virus-cell attachment or a post-entry step of the ZIKV replication cycle. Several studies have attempted to identify the mechanism of inhibition of these natural products. A flavonoid binding pocket was identified on the Dengue virus (DENV) E protein surface, where it was shown that flavonoids such as EGCG, baicalein and baicalin docked in the same region between domain I and domain II of different subunits of E protein. This same flavonoid binding pocket might be present in ZIKV, resulting in many flavonoids being inhibitors of viral entry. The viral E protein is a glycoprotein that mediates virion binding to host cell receptors, inhibition of binding results in inhibition of viral attachment and entry into cells. In addition, the trihydroxyphenyl group on aromatic ring R2 seen in delphinidin and EGCG seem to confer the anti-ZIKV activity, as compounds like catechin and epicatechin lacking the trihydroxyphenyl group do not inhibit ZIKV infection. Another possible explanation is that the mildly acidic nature of the trihydroxyphenyl impairs the acidification of the endosome, inhibiting the release of the viral genome into the host cell cytoplasm. It has also been suggested that the type of sugar bound to the aglycone group of the flavonoid may affect the anti-ZIKV activity of the flavonoid, as seen in isoquercetin versus quercetin. Taken together, the findings point toward possible pharmacophores essential for the inhibition of ZIKV viral entry of these natural products.

Viral replication inhibitors are those that target the postentry stages of the replication cycle, inhibiting ZIKV viral proteins released from the viral capsid or host cell factors involved in viral replication and assembly. Host cell factors such as Golgi-specific Brefeldin A-resistant guanine nucleotide exchange factor 1 (GBF1) involved in Golgi-to-ER recycling and fatty acid synthase have been shown to be crucial in viral replication. Estoppey and colleagues explored the anti-flaviviral effect of cavinafungin, a lipopeptide from the fungus *Colispora cavincola* with IC50 of 150 nM against ZIKV in A549 cells. Through CRISPR/Cas9 chemogenomic profiling, host cell endoplasmic reticulum (ER) signal peptidase was found as the target of cavinafungin. Cavinafungin inhibits the ER signal peptidase, which in turn results in parts of the viral polyprotein precursor not being cleaved to give individual viral proteins (Figure 1). As partially cleaved fragments of the polyprotein are unstable, viral replication is inhibited and viral titre is reduced.
Sinefungin is a structural analogue of S-adenosylmethionine (SAM) produced by Streptomyces griseoleus. SAM is a natural substrate of many methyltransferases, making sinefungin a pan-methyltransferase competitive inhibitor. The ZIKV nonstructural protein NS5 contains a methyltransferase domain which methylates the viral mRNA cap. Coutard and lab demonstrated that sinefungin was able to inhibit ZIKV 2'-O-methyltransferase activity with an IC$_{50}$ of 1.18 ± 0.05 µM via radioactive methyltransferase assay. Subsequently, Hercik and colleagues presented the crystal structure of the ZIKV NS5 methyltransferase domain with sinefungin bound and made suggestions for possible fragment-based drug design that might improve the specificity and binding affinity of sinefungin. Tao and lab followed up with the synthesis of sinefungin derivatives and reported the IC$_{50}$ of certain derivatives in BHK cells to be as low as 6.33 ± 1.93 µM, as compared to sinefungin (IC$_{50}$ > 50 µM).

Suroengrit and colleagues conducted a screen of eight selected flavonoid derivatives (including flavones, flavanones and chalcones) against DENV serotype 2 (DENV2) using plaque titration of the culture supernatants of LLC-MK2 cells. From the screen, FV13 and FV14, two halogenated chrysins, showed strong inhibition of DENV2. Upon further testing with ZIKV, both compounds showed potent anti-ZIKV activity with IC$_{50}$ values of 1.65 ± 0.86 µM and 1.39 ± 0.11 µM, respectively. Further investigations into the mechanism of action of FV13 showed that FV13 acts at the early post-attachment stage, where multiple targets are possible. FV13 and FV14 have more favourable pharmacokinetic profiles than chrysin, with high efficacy and low cytotoxicity, making them ideal inhibitors to further investigate.

Pinocembrin was identified in an immunofluorescence-based high throughput screen of a library of 483 flavonoid derivatives, inhibiting ZIKV infection in JEG-3 cells with an IC$_{50}$ of 17.4 µM. It was reported to decrease both positive- and negative-sense ZIKV RNA levels; Western blot analysis also showed a decrease in ZIKV envelope protein levels. Hence, it is likely that pinocembrin works by inhibiting post-entry stages in the ZIKV replication cycle.

Sophoraflavenone G (SFG) was identified from an extract of Sophora flavescens, a plant used in Chinese medicine, to be able to inhibit ZIKV and DENV replication. An in vitro RdRp activity assay revealed that SFG inhibits ZIKV RdRp with an IC$_{50}$ of 22.61 µM. SFG is a suggested starting hit compound from which lead optimization can be carried out on, as significant levels of cytotoxicity were seen at higher doses of SFG.

Emetine is a drug currently used in the treatment of amebiasis, a parasitic infection of the intestines by Entamoeba histolytica. Emetine can be extracted from the plant Carapichea ipecacuanha, and was identified in a drug-repurposing screen on HEK293 cells (IC$_{50}$: 52.9 nM). Further time-of-addition and ZIKV NS5 polymerase experiments revealed NS5 RdRp to be the target of emetine (IC$_{50}$: 121 nM). In vivo treatment of emetine on two distinct mouse models (SJL and Ifnar1$^{-/-}$) showed an approximate 10-fold decrease in circulating ZIKV. In addition, emetine was also found to disrupt lysosome function. The same study also looked at cephaeline, the structural desmethyl analogue of emetine, which also demonstrated anti-ZIKV properties (IC$_{50}$: 7.60 nM), targeting ZIKV NS5 RdRp (IC$_{50}$: 976 nM) and the autophagy-dependent virus infection pathway.

Lycorine, a benzyl phenethylamine alkaloid, was tested both in vitro on a variety of cell types (EC$_{50}$: 0.22–0.39 µM) and in vivo by Chen et al. Cellular thermal shift assay carried out on ZIKV NS5 showed that lycorine directly binds to ZIKV NS5, inhibiting its RdRp activity and reducing viral RNA replication. Treatment of ZIKV-infected AG6 mice with 10 mg/kg lycorine improved survival rate by 83% and reduced viral RNA in the brain and liver.

Silvestrol is a flavagline isolated from the plant Aglaia foveolate known to inhibit the host cell factor DEAD-box RNA helicase eukaryotic initiation factor-4A (eIF4A), an essential component in viral RNA translation in Ebola virus and coronaviruses. Using immunofluorescence microscopy, Elgner and co-workers showed the dose-dependent reduction in A549-infected cells upon treatment with 5–50 nM of silvestrol. Inhibition of viral RNA translation by silvestrol was shown to be through inhibition of cellular eIF4A.
4.1 | Inhibitors targeting the viral protease

A common target for the development of inhibitors is the ZIKV NS2B-NS3 protease, which is key in the production of mature viral proteins for further viral replication. The nonstructural protein NS3 is a serine protease, with a catalytic site consisting of the triad of serine-135, histidine-51 and aspartate-75. The protease activity of NS3 requires the interaction with the cofactor domain of nonstructural protein NS2B. The NS2B-NS3 viral protease is an attractive target for ZIKV drug discovery as the active site of the protease is highly conserved among other flaviviruses as well, showing promise for the possibility of developing a broad-spectrum flavivirus inhibitor.

Target-based studies beginning with ZIKV NS2B-NS3 protease as a viral target explored compounds that bind to and inhibit protease activity. Often, in vitro biochemical enzymatic assays are performed to characterise the method of inhibition of these compounds.

The antibiotic novobiocin is an aminocoumarin produced by Streptomyces niveus, which acts by inhibiting bacterial DNA gyrase and hence preventing bacterial cell division. In an in silico structure-based screening of 8227 compounds for ZIKV NS2B-NS3 protease inhibitors, novobiocin was identified and validated for its anti-ZIKV activity, with an IC₅₀ of 42.63 µM in Vero cells. Further in vitro studies are consistent with the hypothesis of novobiocin acting on the ZIKV NS2B-NS3 protease. In addition, subcutaneous administration of novobiocin at 100 mg/kg every 12 h from 1 to 13 days post-infection (dpi) to dexamethasone-immunosuppressed mice led to a higher survival rate and lesser weight loss compared to untreated mice. Mean viral loads in the blood and organ tissues were reduced by more than two-log fold in novobiocin-treated mice as compared to untreated mice just 5 dpi.

With ZIKV NS2B-NS3 protease as a target, Roy et al. carried out an in vitro biochemical enzymatic assay of nine natural products. From the enzymatic assay, six compounds were shown to inhibit NS2B-NS3 protease significantly in a non-competitive manner. These six compounds are mainly flavonoids, namely the flavones luteolin (IC₅₀: 2.7 ± 0.3 µM) and apigenin (IC₅₀: 56.3 ± 0.9 µM), flavonols myricetin (IC₅₀: 1.3 ± 0.1 µM), quercetin (IC₅₀: 2.4 ± 0.2 µM) and isorhamnetin (IC₅₀: 15.5 ± 0.7 µM), and the natural phenol curcumin (IC₅₀: 3.5 ± 0.2 µM). Through molecular docking, the explanations for the different IC₅₀ values were elucidated, such as myricetin being the strongest inhibitor as it forms six hydrogen bonds with four different amino acid residues on ZIKV NS3 protease. With the knowledge of key residue interactions and how binding is affected, inhibitors can be better designed with higher affinity for NS2B-NS3 protease.

Also utilising NS2B-NS3 protease as a target, Lim and co-workers performed an in vitro biochemical enzymatic assay with a fluorogenic peptide, determining the inhibition kinetics for 22 polyphenols. Among the 22 polyphenols tested at 100 µM, seven compounds reduced NS2B-NS3 protease activity by more than 40%. These seven compounds were further validated to obtain IC₅₀ values. The compounds are: the flavone luteolin (IC₅₀: 53 ± 1.3 µM), the flavonols myricetin (IC₅₀: 22 ± 0.2 µM), astragalin (IC₅₀: 112 ± 5.5 µM), and rutin (IC₅₀: 104 ± 2.9 µM), the flavanols EGCG (IC₅₀: 87 ± 1.2 µM), epicatechin gallate (IC₅₀: 89 ± 1.6 µM), and gallocatechin gallate (IC₅₀: 99 ± 1.8 µM). Comparing the structures of the compounds and the inhibition values, one of the observations made was that the presence of the hydroxyl group on flavonols is important in the inhibitory activity of flavonols against ZIKV NS2B-NS3 protease.

Naringenin, a flavanone found in several citrus fruits, was shown to inhibit ZIKV replication in A549 cells in a dose-dependent manner with an IC₅₀ of 58.79 µM. Time-of-addition assays revealed the stage naringenin inhibits to be between virus replication and assembly of the ZIKV replication cycle. Molecular docking showed that naringenin can act as a non-competitive inhibitor of the NS2B-NS3 viral protease, which could be a possible target of naringenin. The low bioavailability of naringenin prompted the study of chemical derivatives of naringenin by Mendes and colleagues, where ether derivatives demonstrated anti-ZIKV effects on A549-infected cells (IC₅₀ values range from 6.76 to 69.33 µM). However, these ether derivatives were shown to have higher toxicity than that of naringenin.
The suggested SAR for flavonoids against ZIKV NS2B-NS3 protease has been researched on in multiple studies, with results being in agreement with each other. Continuing on from the SAR established for viral entry, Zou and colleagues extended the pharmacophore region of flavonoids beyond the trihydroxyphenyl group to include the ester functional group (galloyl group). In addition, Lim and co-workers established a similar SAR as Zou where the presence of hydroxyl groups at C3′, C4′, and C5′ of the B-ring is key in the inhibition of NS2B-NS3 protease. As opposed to the findings from Gaudry et al., glycosylation at C7 of the A-ring decreases NS2B-NS3 protease inhibition, though this glycosylation may be important in inhibiting viral entry instead. The binding pocket of these flavonoids on the ZIKV NS2B-NS3 protease complex is likely to be on an allosteric site, based on the enzyme kinetics performed by Roy and colleagues.

5 | INHIBITORS WITH UNKNOWN TARGETS

Inhibitors with unknown targets were identified in phenotypic screening assays, which are a common way of identifying potential antivirals. A large number of compounds can be tested, increasing the probability of identifying a hit inhibiting ZIKV infection with acceptable IC50 and CC50 values. Improvements in technology have enabled the establishment of high throughput screening assays that are becoming increasingly cost-efficient and improving in accuracy.

A marinopyrrole derivative was identified from a screen of a library of natural product derivatives carried out by Bernatchez and co-workers. This compound was obtained after structural simplification and optimization studies on marinopyroles, which are produced by Actinomycete strain CNQ-418. Of the 24 compounds screened, one was able to reduce cytopathic effect (CPE) in Vero cells with an EC50 of 5.95 ± 0.72 µM.

Kitasamycin was identified in a high-content immunofluorescence screening of U.S. Food and Drug Administration (FDA)-approved drugs. Kitasamycin is a macrolide antibiotic produced by Streptomyces narbonensis, and has been shown to inhibit Gram-positive bacteria and mycoplasma by binding to bacterial ribosomal RNA, hence inhibiting bacterial protein synthesis. Though the mechanism of the anti-ZIKV effect of kitasamycin is still unknown, the measured EC50 is 41.7 ± 10.1 µM in Huh7 cells, indicating the potential of kitasamycin as a promising compound with anti-ZIKV activity.

Hippeastrine hydrobromide (HH), first isolated from Lycoris radiata, is another steroidal alkaloid identified in a high-content chemical screen using human pluripotent stem cell-derived cortical neural progenitor cells (IC50: 1.95 µM). In a human fetal-like forebrain organoid model, treatment with 25 µM of HH for 3 days was effective in reducing the percentage of cells infected with ZIKV. This is especially important as ZIKV infection is often associated with neurological disorders. This finding was further shown in severe combined immunodeficiency beige (SCID-beige) mice, where immunohistochemical analysis revealed that HH was able to reduce infection in various regions of the brain. However, the mechanism of action of HH remains to be investigated.

18-oxoferruginol is an abietane diterpenoid whose anti-ZIKV activity was evaluated in vitro. Among the abietane analogues tested, 18-oxoferruginol presented the best selectivity index of 13.51 with a CC50 value of 35.09 ± 5.20 µM and an EC50 value of 2.60 ± 0.07 µM.

Instead of isolated compounds, several studies also investigated the anti-ZIKV effect of plant extracts as a starting point for the identification of novel anti-ZIKV agents. Most of these extracts are polyphenol-rich, such as extracts from Polygonum cuspidatum, Psiloxylon mauritianum, Schinus terebenthifolius Raddi, Punica granatum, Doratoxylon apetalum, Aphiolda theiformis, and silymarin, an extract from the plant Silybum marianum L. Gaertn. From these extracts, natural products with novel chemical scaffolds can be identified. For instance, Kuo et al. showed the anti-flaviviral activity of the methanolic extract from Polygonum cuspidatum, in which major constituents include quercetin, resveratrol, and emodin. Flow cytometry-based infection analysis on Vero-infected cells showed the significant inhibition of ZIKV entry by this P. cuspidatum extract.
CONCLUSION AND FUTURE PERSPECTIVES

Ever since the first outbreak of ZIKV in Micronesia in 2007, much research has been carried out in identifying anti-ZIKV compounds, through drug-repurposing screens or looking to the relatively untapped source of natural compounds. Natural products of microbial, plant and marine origins have great structural diversity, as evidenced by the many chemical classes. This allows for the discovery of novel chemical scaffolds which can serve as parent compounds for further SAR investigations to further improve on the efficacy and safety profile of the compound through synthetic processes. This method of identifying hit compounds saves time as these molecules have evolutionary preoptimized biological targets, increasing the prospect of identifying a positive hit.

As shown by the 44 isolated compounds and six plant extracts discussed in the earlier sections, current knowledge of the anti-ZIKV natural products show that these compounds target different stages in the ZIKV replication cycle, ranging from host cell factors such as eIF4A to ZIKV viral proteins such as the NS2B-NS3 protease. This, therefore, raises the possibility of combinatorial therapy in the treatment of ZIKV infections to increase the efficacy of treatment. This has been explored by Gao et al. in the combinatorial effects of gossypol with other natural products such as curcumin. Results show a two- to threefold enhancement in the inhibition of ZIKV infection in Vero cells, with little effect on cytotoxicity. High synergism was observed when both D. menstrualis acetylated crude extract fraction FAc-2 and ribavirin, a synthetic nucleoside with known antiviral activity against other RNA and DNA viruses, were added together. ZIKV replication was inhibited by around 90%, which was much more than the addition of the compounds effects of these compounds individually. Many of these natural products isolated are flavonoids or polyphenols, whose antiviral activity is known to be caused by hydrogen bond interactions of the phenolic hydroxyl groups with viral or host cell factors. Strategies to improve the inhibitory activity of these natural products include improving lipophilicity for greater interaction with biological membranes and better permeability of the compound into the host cell. However, these structural modifications should also take into account the current established SAR of these flavonoids, such as the number and positions of hydroxyl groups, the hybridization of carbons, and the glycosylation of the compound.

Nonetheless, there are still certain areas of research that provide great potential in the discovery of ZIKV natural product antivirals, such as marine sources of natural products. The marine environment has also been another important source of natural products, providing several compounds that have been approved by FDA as antibiotics and anticancer drugs. Sources of these natural products include marine microorganisms, algae, sponges, jellyfish and rocky corals. Marine natural products as ZIKV antivirals are still a relatively unexplored area, which is surprising as organisms in the marine environment such as marine actinomycetes and cyanobacteria have provided many compounds that have progressed into clinical trials and even been approved for clinical use. This could be due to perceived challenges presented by natural product drug discovery, such as the extra resources and time required to isolate and identify compounds responsible for the antiviral effect. For compounds with moderate to high complexity, chemical synthesis might not be a viable option. However, with the development of better technology, it has become much easier. It was reported that with the relevant skills and resources, the structures of individual compounds in extracts can be solved within 2 weeks.

In many studies the in vitro antiviral assays were only tested in a particular cell line or only using a particular ZIKV strain as shown in Table 1. Thus, the results of the compound may be cell line- or strain-specific instead, which renders the compound ineffective in treating ZIKV infection where ZIKV infects a variety of cell types. This is particularly important as there have been significant differences observed in the pathogenesis of African ZIKV strains as compared to Asian strains. For example, Aubry et al. reported that African ZIKV strains are more transmissible by mosquitoes, and are associated with fetal loss rather than birth defects. Differences in growth ability were also reported, where the African ZIKV strains showed greater ability to infect human placental trophoblasts. Hence, it would be interesting to explore the differences in drug effect across these different ZIKV strains, particularly comparing between the African and Asian lineages.
Additionally, more work in characterising the activity of the compound in several representative cell types is required, before taking the compound forward to in vivo studies. Several of these compounds have only been tested in cell-free systems against particular ZIKV proteins such as the NS2B-NS3 protease, which does not rule out the possibility of secondary drug targets, such as other viral or host factors. At the same time, preliminary information on the pharmacokinetic properties of the drug is not considered. The advantage, however, of using purified viral proteins is in the ability to determine the mode of inhibition of the drug, where further characterisation of specific molecular interactions of the pharmacophores and amino acid residues can be elucidated. As the end goal is still towards testing in living organisms, further validation in cell culture is essential. Majority of the studies perform cell-based assays by infecting cell lines with ZIKV and quantifying reduction in viral titre via plaque assays. A common choice of cell line is Vero, a kidney epithelial cell line obtained from the African green monkey. Although Vero is derived from normal kidney cells and not immortal cells, its origin is non-human. Hence, evaluating the drug effect in other immortalised human cell lines or in primary human cell lines is necessary. Although human A549 was shown to be as effective as Vero E6 in its susceptibility to ZIKV infection, more physiologically relevant cell lines can be used, such as the human brain microvascular endothelial cells used by Rausch et al.56,104 Such cell lines will be helpful in replicating the natural host environment of ZIKV.

In any drug discovery programme, in vivo testing in animal models is essential in evaluating the pharmacokinetic properties of the compound—understanding its preclinical safety and efficacy profile and establish a therapeutic dose. Of the 44 natural compounds highlighted, only six of these compounds have been tested in mouse models.38,57,72,73,80,88 Though the particular mouse models used differ, the mice are all immunocompromised, either with double knockout of the Ifnar1 gene or dexamethasone-immunosuppressed. This is because it is known that mice with genetic knockouts in the type I interferon signalling pathway are more susceptible to flavivirus infection.105 However, ethical concerns arising from the use of animal models present a high barrier to entry. Furthermore, inter-species biological differences may skew the results obtained.

To circumvent and improve on existing limitations of animal models, three-dimensional (3D) cell cultures and organoid models have been developed. In the study by Zhou and colleagues, a human pluripotent stem cell-derived forebrain organoid model was utilised to study the effect of hippeastrine hydrobromide on ZIKV infection in the brain.88 This organoid model is used in the study of brain disorders such as microcephaly, which is one of the possible effects of severe ZIKV infection.106 Especially for complex organs like the brain, two-dimensional monolayer or free-floating neurosphere cell cultures might not be able to replicate the same diversity and composition of the various cell types that constitute the organ. Being able to mimic the in vivo physiology with lesser ethical concerns make organoid cultures an ideal model system for antiviral development. Nonetheless, culturing organoids is still a relatively new technique, requiring extensive training and equipment. Specialised equipment to visualise readouts is required, especially if the study is focused on particular segments of the 3D culture. Issues with regards to accessing the target host cell receptors and visualising CPE have also been raised.107 Finally, studying organoids in isolation neglects interactions arising from the immune and circulatory system being connected to organ, which may affect the results of ZIKV infection.

Several of these natural products may still require optimisation of their pharmacokinetic properties. For instance, Batista and colleagues have recognised the barriers in bringing the natural products berberine and emodin forward in pharmaceutical development, such as low aqueous solubility and bioavailability.49 For this reason, the development of semisynthetic or synthetic structures which were conceptually derived from a natural product have been on the rise, where a natural product compound is used as a start point for the introduction of synthetic modifications.108 This was explored in a few of the studies with chemically modified flavones68 or ethers and esters lipophilic naringenin derivatives.85

In areas where ZIKV infection is endemic, coinfections with other arboviruses such as DENV and the West Nile virus (WNV) are common.109 This is an additional concern as DENV-specific antibodies have been reported to result in a higher susceptibility to ZIKV infection by the Brazilian isolate through the antibody-dependent enhancement
mechanism. Thus, it is worthwhile to consider looking at natural products that can act as antivirals against a broad-spectrum of arboviruses instead of just ZIKV in isolation, as carried out by numerous studies.38,45,56, 64,68,90

To conclude, viral infections are seasonal in that there are cyclical patterns in infectiousness due to changes in pathogen survival rates and host susceptibility.111 Although there seems to be a decrease in the number of reported cases of ZIKV infection, as long as the vectors for ZIKV infection continue to exist, the search for antivirals against ZIKV remains an urgent need. Moreover, ZIKV infection could also occur vertically from mother to fetus. Hence, research on ZIKV antivirals should continue to prevent future outbreaks. Natural products have lower costs of production, are environmentally friendly, and tend to have more favourable physicochemical properties such as lower cytotoxicity compared to synthetic compounds. This is especially important as ZIKV infections tend to be endemic in developing countries, where cost is an important factor in considering the available therapeutic options. Furthermore, as ZIKV infection has been associated with fetal microcephaly, the patient profile of anti-ZIKV drugs includes pregnant women, indicating the need for a more favourable safety profile. Hence, natural products are a viable source of antivirals against ZIKV infection, which continues to be a persistent epidemic worldwide.

ACKNOWLEDGEMENTS
This research received no external funding, and the authors declare no conflict of interest. This study is supported by MOE Tier 2 2017 (MOE2017-T2-1-078; MOE2017-T2-2-014) and NRF-CRP21-2018-0004.

DATA AVAILABILITY STATEMENT
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.

ORCID
Yuhui Deborah Fong https://orcid.org/0000-0002-6784-8896
Justin Jang Hann Chu http://orcid.org/0000-0002-1673-6819

REFERENCES
1. Westaway EG, Brinton MA, Gaidamovich SY, et al. Flaviviridae. Intervirology. 1985;24:183-192.
2. Campos GS, Bandeira AC, Sardi SI. Zika Virus Outbreak, Bahia, Brazil. Emerg Infect Dis. 2015;21:1885-1886.
3. Hennessey M, Fischer M, Staples JE. Zika virus spreads to new areas-region of the Americas, May 2015-January 2016. MMWR Morb Mortal Wkly Rep. 2016;65:55-58.
4. Grand G, Caron M, Mambo IM, et al. Zika Virus in Gabon (Central Africa)—2007: A New Threat from Aedes albopictus. PLoS Negl Trop Dis. 2014;8:1-6.
5. Olson JG, Ksiazek TG, Suhandiman G, Triwibowo V. Zika virus, a cause of fever in Central Java, Indonesia. Trans R Soc Trop Med Hyg. 1981;75:389-393.
6. World Health Organization. WHO. 2019;2019.
7. Oehler E, Watrin L, Larre P, et al. Zika virus infection complicated by Guillain-Barré syndrome—case report, French Polynesia, December 2013. Euro Surveill. 2014;19:1-3.
8. Cao-Lormeau VM, Roche C, Teissier A, et al. Zika virus, French polynesia, South pacific, 2013. Emerg Infect Dis. 2014;20:1085-1086.
9. Cauchemez S, Besnard M, Bom bard P, et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet. 2016;387:2125-2132.
10. World Health Organization, WHO.
11. Musso D, Nilles EJ, Cao-Lormeau VM. Rapid spread of emerging Zika virus in the Pacific area. Clin Microbiol Infect. 2014;20:0595-0596.
12. Duffy MR, Chen T-H, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360:2536-2543.
13. Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau V-M. Potential sexual transmission of Zika virus. Emerg Infect Dis. 2015;21:359-361.
14. Schuler-Faccini L, Ribeiro EM, Feitosa IML, et al. Possible association between Zika virus infection and microcephaly—Brazil, 2015. MMWR Morb Mortal Wkly Rep. 2016;65:59-62.
15. Dirlikov E, Major CG, Mayshack M, et al. Guillain-Barré Syndrome during ongoing Zika virus transmission—Puerto Rico, January 1–July 31, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:910-914.

16. Martines RB, Bhatnagar J, de Oliveira Ramos AM, et al. Pathology of congenital Zika syndrome in Brazil: a case series. Lancet. 2016;388:898-904.

17. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus and birth defects—reviewing the evidence for causality. N Engl J Med. 2016;374:1981-1987.

18. Chen T, He X, Zhang P, et al. Research advancements in the neurological presentation of flaviviruses. Rev Med Virol. 2019;29:1-12.

19. Alam A, Imam N, farooqui A, Ali S, Malik MZ, Ishrat R. Recent trends in ZikV research: a step away from cure. Biomed Pharmacother. 2017;91:1152-1159.

20. Wahid B, Ali A, Rafique S, Idrees M. Current status of therapeutic and vaccine approaches against Zika virus. Eur J Intern Med. 2017;44:12-18.

21. Munjal A, Khandia R, Dhamla K, et al. Advances in developing therapies to combat Zika virus: current knowledge and future perspectives. Front Microbiol. 2017;8:1-19.

22. Carneiro BM, Batista MN, Braga ACS, Nogueira ML, Rahal P. The green tea molecule EGCG inhibits Zika virus entry. Virology. 2016;496:215-218.

23. Wright GD. Unlocking the potential of natural products in drug discovery. Microb Biotechnol. 2019;12:55-57.

24. Motika SE, Hergenrother PJ. Re-engineering natural products to engage new biological targets. Nat Prod Rep. 2020;37:1395-1403. doi:10.1039/d0np00059k

25. Shen B. A new golden age of natural products drug discovery. Expert Opin Investig Drugs. 2009;9:2103-2119.

26. Wang HK. The therapeutic potential of flavonoids. Cell. 2015;163:1297-1300.

27. Abdel-Razek AS, EL-Naggar ME, Allam A, Morsy OM, Othman SI. Microbial natural products in drug discovery. Processes. 2020;8:1-19.

28. Yi M, Lin S, Zhang B, Jin H, Ding L. Antiviral potential of natural products from marine microbes. Eur J Med Chem. 2020;207:112790.

29. Sager G, Gabaglio S, Sztul E, Belov GA. Role of host cell secretory machinery in Zika Virus Life Cycle. Viruses. 2018;10:2013-2014.

30. Rodríguez AK, Muñoz AL, Segura NA, Rangel HR, Bello F. Molecular characteristics and replication mechanism of dengue, Zika and chikungunya arboviruses, and their treatments with natural extracts from plants: an updated review. EXCLI J. 2019;18:988-1006.

31. Hossein F. An overview of the current medical literature on Zika virus. Biophys Rev. 2020;12:1133-1138.

32. Meertens L, Labeau A, Dejarnac O, et al. Axl mediates ZIKV entry in human glial cells and modulates innate immune responses. Cell Rep. 2017;18:324-333.

33. Meertens L, Labeau A, Dejarnac O, et al. AXL mediates ZIKV entry in human glial cells and modulates innate immune responses. Cell Rep. 2017;18:324-333.

34. Kaufmann B, Rossmann MG. Molecular mechanisms involved in the early steps of flavivirus cell entry. Microbes Infect. 2011;13:1-9.

35. Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol. 1990;44:649-88.

36. Agrell A, de Moura RR, Crovella S, Brandão LAC. ZIKV virus entry mechanisms in human cells. Infect Genet Evol. 2019;69:22-29.

37. Zhou Y, Simmons G. Development of novel entry inhibitors targeting emerging viruses. Expert Rev Anti Infect Ther. 2012;10:1129-1138.

38. Prochnow H, Rox K, Birudukota NVS, et al. Labyrinthopeptins exert broad-spectrum antiviral activity through lipid-binding-mediated virolysis. J Virol. 2020;94:1-24.

39. Cirne-Santos CC, Barros CDS, Gomes MWL, et al. Nat Prod Commun. 2019;14:1-7.

40. Pereira HS, Leão-Ferreira LR, Moussatché N, et al. Antiviral activity of diterpenes isolated from the Brazilian marine alga Dictyota menstrualis against human immunodeficiency virus type 1 (HIV-1). Antiviral Res. 2004;64:69-76.

41. De Souza Pereira H, Leao-Ferreira LR, Moussatche N, et al. Effects of diterpenes isolated from the Brazilian marine alga Dictyota menstrualis on HIV-1 reverse transcriptase. Planta Med. 2005;71:1019-1024.

42. Steinmann J, Buer J, Pietschmann T, Steinmann E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol. 2013;168:1059-1073.

43. Sharma N, Murali A, Singh SK, Girii R. Epigallocatechin gallate, an active green tea compound inhibits the Zika virus entry into host cells via binding the envelope protein. Int J Biol Macromol. 2017;104:1046-1054.

44. Kumar D, Sharma N, Aarthy M, Singh SK, Girii R. Mechanistic insights into ZIka Virus NS3 helicase inhibition by epigallocatechin-3-Gallate. ACS Omega. 2020;5:11217-11226.
54. Vázquez-Calvo A, de Oya NJ, Martín-Acebes MA, García-Moruno E, Saiz JC. Antiviral properties of the natural Polyphenols Delphinidin and Epigallocatechin Gallate against the Flaviviruses West Nile Virus, Zika Virus, and Dengue Virus. Front Microbiol. 2017;8:1-8.

55. Rausch K, Hacket B, Weinbren N, et al. Screening bioactives reveals nanchangmycin as a broad spectrum antiviral.

56. Wong G, He S, Siragam V, et al. Antiviral activity of quercetin.

57. Mohd A, Zainal N, Tan KK, AbuBakar S. Resveratrol affects Zika virus replication in vitro.

58. Lai ZZ, Ho YJ, Lu JW. Cephalotaxine inhibits Zika infection by impeding viral replication and stability.

59. Zou M, Liu H, Li J, et al. Structure.

60. Lee JK, Shin OS. Int J Mol Sci. 2019;20:1

61. Mounce BC, Cesaro T, Carrau L, Vallet T, Vignuzzi M. Curcumin inhibits Zika and chikungunya virus infection by

62. Ismail NA, Jusoh SA. Molecular docking and molecular dynamics simulation studies to predict flavonoid binding on the surface of DENV2 E protein. Interdiscip Sci: Comput Life Sci. 2016;9:499-511.

63. Acquaro S, Civra A, Caglieri C, et al. Punica granatum leaf ethanolic extract and ellagic acid as inhibitors of Zika virus infection. Planta Med. 2020;86:1363-1374. doi:10.1055/a-1232-5705

64. Zorofchian Moghadamtousi S, Abdul Kadir H, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. BioMed Res Int. 2014;2014:1-12.

65. Martín Calvo A, de Oya NJ, Martín-Acebes MA, García-Moruno E, Saiz JC. Antiviral properties of the natural Polyphenols Delphinidin and Epigallocatechin Gallate against the Flaviviruses West Nile Virus, Zika Virus, and Dengue Virus. Front Microbiol. 2017;8:1-8.

66. Hercik K, Brynda J, Nencka R, Boura E. Structural basis of Zika virus methyltransferase inhibition by sinefungin.

67. Tao Z, Cao R, Yan Y, et al. Design, synthesis and in vitro anti-Zika virus evaluation of novel Sinefungin derivatives. Eur J Med Chem. 2018;157:994-1004.

68. Suroengrit A, Yutthithammon W, Srirangakul P, et al. Halogenated Chrysins Inhibit Dengue and Zika virus infectivity. Sci Rep. 2017;7:1-11.

69. Le Lee J, Loe MWC, Lee RCH, Chu JJH. Antiviral activity of pinocembrin against Zika virus replication. Antiviral Res. 2019;167:13-24.

70. Sze A, Olagnier D, Hadj SB, et al. Sophoraflavenone G restricts Dengue and Zika virus infection via RNA polymerase interference. Viruses. 2017;9:1-7.

71. Scholar E. in xPharm: The Comprehensive Pharmacology Reference. Elsevier Inc; 2009:1-4.

72. Yang S, Xu M, Lee EM, et al. Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry. Cell Discov. 2018;4:1-14.

73. Chen H, Lao Z, Xu J, et al. Antiviral activity of 1,2-lycorine against Zika virus in vivo and in vitro. Virology. 2020;546:88-97.

74. Chu J, Galicia-Vázquez G, Cencic R, et al. CRISPR-mediated drug-target validation reveals selective pharmacological inhibition of the RNA helicase, eIF4A. Cell Rep. 2016;15:2340-2347.
75. Elgener F, Sabino C, Basic M, Ploen D, Grünweller A, Hildt E. Inhibition of Zika virus replication by silvestrol. Viruses. 2018;10:1-14.
76. H S, R H. Recent advances in targeting viral proteases for the discovery of novel antivirals. Curr Top Med Chem. 2010;10:323-345.
77. Hsu J, Wang H-C, Chen G-W, Shih S-R. Antiviral drug discovery targeting to viral proteases. Curr Pharm Des. 2006;12:1301-1314.
78. Voss S, Nitsche C. Inhibitors of the Zika virus protease NS2B-NS3. Biorg Med Chem Lett. 2020;30:126965.
79. Nitsche C. Proteases from dengue, West Nile and Zika viruses as drug targets. Biophys Rev. 2019;11:157-165.
80. Yuan S, Chan JFW, Den-Haan H, et al. Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and in vivo. Antiviral Res. 2017;145:33-43.
81. Salesi B, Fokou PVT, Sharifi-Rad M, et al. The therapeutic potential of naringenin: a review of clinical trials. Pharmaceuticals. 2019;12:1-18.
82. de LA, Mendes O, Ponciano CS, et al. The anti-Zika virus and anti-tumoral activity of the citrus flavanone lipophilic naringenin-based compounds. Chem Biol Interact. 2020;331:1-12.
83. Bernatchez JA, Yang Z, Coste M, et al. Development and validation of a phenotypic high-content imaging assay for assessing the antiviral activity of small-molecule inhibitors targeting Zika Virus. Antimicrob Agents Chemother. 2018;62:1-11.
84. Pascoalino BS, Courtemanche G, Cordeiro MT, Gil LHVG, Freitas‐‐. Biotechnol Lett. 2017;39:415-421.
85. Cataneo AHD, Kuczera D, Koishi AC, et al. The citrus flavonoid naringenin impairs the in vitro infection of human cells by Zika virus. Sci Rep. 2019;9:1-15.
86. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972;177:705-706.
87. Li R. Marinospyrroles: unique drug discoveries based on marine natural products. Med Res Rev. 2016;36:169-189.
88. Pereira F. Have marine natural product drug discovery efforts been productive and how can we improve their efficiency? Expert Opin. Drug Discov. 2019;14:717-722.
89. Carroll AR, Copp BR, Davis RA, Keyzers RA, Prinsep MR. Marine natural products. Nat Prod Rep. 2019;36:122-173.
90. Abdelmohsen UR, Balasubramanian S, Oelschlaeger TA, et al. Potential of marine natural products against drug-resistant fungal, viral, and parasitic infections. Lancet Infect Dis. 2017;17:e30-e41.
91. Singh SB, Barrett JF. Empirical antibacterial drug discovery--foundation in natural products. Biochem Pharmacol. 2006;71:1066-1075.
92. Aubry F, Jacobs S, Darmuzey M, et al. Recent African strains of Zika virus display higher transmissibility and fetal pathogenicity than Asian strains. Nat Commun. 2021;12:1-14.
93. Sheridan MA, Balaraman V, Schust DJ, Ezashi T, Michael Roberts R, Franz AWE. PLoS One. 2018;13:1-18.
94. Vicenti I, Boccuto A, Giannini A, Dragoni F, Saladini F, Zazzi M. Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro. Virus Res. 2018;244:64-70.
105. Dowall SD, Graham VA, Rayner E, et al. PLoS Negl Trop Dis doi:10.1371/JOURNAL.PNTD.0004658
106. Bershtein M, Kriegstein AR. Cerebral organoids in a dish: progress and prospects. Cell. 2013;155:19-20.
107. Sridhar A, Simmini S, Ribeiro CMS, et al. A perspective on organoids for virology research. Viruses. 2020;12:1-10.
108. Patridge E, Gareiss P, Kinch MS, Hoyer D. An analysis of FDA-approved drugs: natural products and their derivatives. Drug Discov Today. 2016;21:204-207.
109. Mercado-Reyes M, Acosta-Reyes J, Navarro-Lechuga E, et al. Dengue, chikungunya and zika virus coinfection: results of the national surveillance during the zika epidemic in Colombia. Epidemiol Infect. 2019;147:1-7.
110. Castanha PMS, Nascimento EJM, Braga C, et al. Dengue Virus-Specific Antibodies Enhance Brazilian Zika Virus Infection. J Infect Dis. 2017;215:781-785.
111. Fisman D. Seasonality of viral infections: mechanisms and unknowns. Clin Microbiol Infect. 2012;18:946-954.

AUTHOR BIOGRAPHIES

Yuhui Deborah Fong graduated with a B.Sc. in Life Sciences (2020) and is currently doing her PhD at National University of Singapore (NUS) with Associate Professor Justin Jang Hann Chu. She is currently exploring the screening of compounds to identify antivirals against human enteroviruses.

Associate Professor Justin Jang Hann Chu is currently the Assistant Dean for Academic Affairs and a faculty member in the Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore https://medicine.nus.edu.sg/mbio/about-us/our-people/academic-staff/justin-chu.html. He is holding a Joint Senior Principal Investigator in the Institute of Molecular and Cell Biology (IMCB), A*STAR. A/P Chu is also the Director of the largest research based high containment Biosafety Level 3 Facility in Singapore which is located in the Yong Loo Lin School of Medicine, NUS. A/P Chu is actively engaged in the study of the molecular biology of human enteroviruses that cause HFMD as well as mosquito-borne viruses including Dengue, Zika, Japanese Encephalitis and Chikungunya. The outcomes of these studies are helping to pave the roadmap towards the development of a number of antiviral strategies. Eight patents and numerous scientific awards have been received from his current research. A/P Chu has published over 100 international peer-reviewed scientific publications, six book chapters and over 150 conference papers. A number of these scientific papers are published in prestigious journals including Science, Science Translational Medicine, Nature Communications, PNAS, PLoS Pathogens. A/P Chu is currently serving as the associate editor and reviewer for a number of peer-reviewed journals in the areas of medical virology and anti-viral strategies. He is the current President of the Asia-Pacific Society of Medical Virology and the President of the Singapore Society for Microbiology and Biotechnology.

How to cite this article: Fong YD, Chu JJH. Natural products as Zika antivirals. Med Res Rev. 2022;42:1739-1780. doi:10.1002/med.21891